trending Market Intelligence /marketintelligence/en/news-insights/trending/XeKOSdgmaS8HRj2E-fibSw2 content esgSubNav
In This List

Antares submits new drug application to FDA for Quickshot Testosterone

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Antares submits new drug application to FDA for Quickshot Testosterone

Antares Pharma Inc. submitted a new drug application to the U.S. FDA for its QuickShot Testosterone, a drug-device combination product for treating men with low testosterone associated with hypogonadism.

The product delivers testosterone enanthate using a subcutaneous auto injector.